Analyst Ratings February 24, 2026

Jefferies Lifts Home Depot Target, Cites Early-Stage Housing Recovery

Analyst raises price objective to $454 as company posts stronger-than-expected Q4 2025 results and consistent comps across regions

By Caleb Monroe HD
Jefferies Lifts Home Depot Target, Cites Early-Stage Housing Recovery
HD

Jefferies increased its price target for Home Depot to $454 from $424 and kept a Buy rating, pointing to management comments about consistent comparable sales across regions with differing home-price trends. The firm views the lack of regional dispersion as evidence that the housing recovery is still in its early phase and projects sustained EPS growth beginning in 2027. Other broker updates and quarterly results underline investor confidence, even as valuation questions persist.

Key Points

  • Jefferies raised its Home Depot price target to $454 from $424 and kept a Buy rating; Jefferies cites steady comparable sales across regions with differing home-price movements.
  • Jefferies expects high single-digit to low double-digit EPS growth for consecutive years starting in 2027; Truist also raised its target to $424 after better-than-expected Q4 2025 results.
  • Home Depot posted adjusted EPS of $2.72 and revenue of $38.2 billion for Q4 2025, and recorded positive U.S. comparable sales throughout calendar year 2025 despite tougher comparisons and no storm-driven demand.

Jefferies has raised its price target on Home Depot stock (NYSE:HD) to $454 from $424 while keeping a Buy rating on the shares. The company shares currently trade at $384.71, translating to a market capitalization of $382.6 billion and a price-to-earnings ratio of 26.25.

In explaining the change, Jefferies pointed to management commentary that highlighted steady comparable sales patterns across different geographic areas, despite those markets facing varied movements in home prices. The firm noted that the absence of significant regional performance dispersion supports its assessment that the housing recovery is still in its early stages.

Looking further ahead, Jefferies projects that Home Depot will deliver high single-digit to low double-digit percentage growth in earnings per share for consecutive years beginning in calendar year 2027. The firm reiterated its Buy recommendation on the home improvement retailer.

Separately, analysis available through InvestingPro indicates that Home Depot appears overvalued at current market levels. The Pro Research Report also flags that the company has increased its dividend for 16 consecutive years, a detail presented among other findings in the comprehensive report.


Home Depot's most recent earnings report for the fourth quarter of 2025 showed results above Wall Street expectations. The company posted adjusted earnings per share of $2.72, ahead of the $2.54 consensus, and reported revenue of $38.2 billion compared with the forecasted $38.14 billion. Those outcomes were described as evidence of the firm's resilience in a challenging retail setting.

Following the quarterly results, Truist Securities raised its price target on Home Depot to $424 from $405 and maintained a Buy rating. Truist attributed the revision to the solid fourth-quarter performance and a modest increase in January sales.

Home Depot also delivered positive U.S. comparable sales for each month of calendar year 2025. Management noted these gains occurred despite the absence of storm-related demand and against progressively tougher year-over-year comparisons in the latter part of the year.

Taken together, the analyst upgrades, reaffirmations of Buy ratings, and quarterly outperformance underline continued investor interest in the company. At the same time, available valuation analysis suggests the stock may already price in a considerable portion of expected improvement.

Risks

  • Valuation concerns - InvestingPro analysis indicates Home Depot appears overvalued at current market levels, which could limit upside for investors.
  • Housing recovery uncertainty - Jefferies describes the housing recovery as being in early stages; if the recovery stalls or regional dynamics shift, earnings forecasts could be affected.
  • Comparative sales pressure - Management noted more difficult year-over-year comparisons in the latter half of 2025, which could challenge future comparable sales momentum.

More from Analyst Ratings

Raymond James Cuts FIS Price Target After Margin Shortfall; Shares Near 52-Week Low Feb 24, 2026 Texas Capital Starts Coverage on Angel Studios with Buy Rating and $6.50 Target Feb 24, 2026 Mizuho Moves Neptune Insurance to Neutral, Cites Limited AI Risk but Flags Valuation and Competition Feb 24, 2026 RBC Capital Starts Merck Coverage at Outperform, Sets $142 Target on Pipeline Momentum Feb 24, 2026 Stifel Starts Coverage of Palisade Bio with Buy Rating, Cites IBD Opportunity for PALI-2108 Feb 24, 2026